CNR2 Inhibitors

Chemical inhibitors of CNR2 include a variety of compounds that specifically target this protein to inhibit its function. AM630 is one such compound, acting as an inverse agonist to CNR2, which means it binds to the receptor and induces a conformational change that prevents the normal action of the receptor, effectively turning off its constitutive activity. Similarly, JTE907 serves to decrease intracellular signaling by binding to CNR2 in a way that blocks its activation, acting as an inverse agonist. SR144528 and BML-190 both selectively antagonize CNR2. SR144528's interaction with CNR2 inhibits the signaling pathways that the receptor normally engages upon activation. BML-190 achieves inhibition of CNR2 by preventing the receptor from being activated by its endogenous ligands. HU 308 and LY320135 function as antagonists to CNR2 as well, with HU 308 inhibiting the biological activities CNR2 mediates, and LY320135 reducing the receptor's activity through its antagonistic action.

Continuing with the suite of CNR2 inhibitors, CAY10402 and AM6545 both act as selective antagonists. CAY10402 binds to CNR2 in a way that inhibits the receptor's function without affecting similar receptors. AM6545 is a peripherally restricted compound, which means it inhibits CNR2's activity in peripheral tissues without crossing the blood-brain barrier to affect central CNR2 receptors. Hemopressin is a peptide inhibitor that exerts its effects allosterically on CNR2, meaning that it binds to a different site than the endogenous ligand would, causing an inhibitory effect on the receptor's function. Ajulemic acid is another compound that binds as an inverse agonist to CNR2, thereby inhibiting its signaling. SMM-189 was designed to selectively antagonize CNR2 and inhibit its action specifically within the central nervous system. Lastly, PSB-SB-1202 acts as an antagonist to CNR2, effectively inhibiting the receptor's function and signaling pathways. Each of these chemicals interacts with CNR2 in a manner that inhibits the receptor's normal activity, thereby reducing the various physiological responses that CNR2 mediates.